Compare AA & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AA | ELAN |
|---|---|---|
| Founded | 1888 | 1954 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aluminum | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 12.4B |
| IPO Year | 2016 | 2018 |
| Metric | AA | ELAN |
|---|---|---|
| Price | $51.72 | $23.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | ★ $67.20 | $27.89 |
| AVG Volume (30 Days) | 4.6M | ★ 7.4M |
| Earning Date | 04-16-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.64% | N/A |
| EPS Growth | ★ 1580.77 | N/A |
| EPS | ★ 3.13 | 0.22 |
| Revenue | ★ $12,831,000,000.00 | $4,715,000,000.00 |
| Revenue This Year | $16.05 | $8.21 |
| Revenue Next Year | N/A | $5.31 |
| P/E Ratio | ★ $15.97 | $107.61 |
| Revenue Growth | ★ 7.87 | 6.22 |
| 52 Week Low | $28.92 | $17.11 |
| 52 Week High | $84.38 | $27.98 |
| Indicator | AA | ELAN |
|---|---|---|
| Relative Strength Index (RSI) | 53.64 | 44.30 |
| Support Level | $42.61 | $23.24 |
| Resistance Level | $50.87 | $23.48 |
| Average True Range (ATR) | 1.59 | 1.16 |
| MACD | 0.96 | -0.25 |
| Stochastic Oscillator | 66.03 | 30.63 |
Alcoa is a vertically integrated aluminum company whose operations include bauxite mining, alumina refining, and manufacturing primary aluminum. It is one of the world's largest bauxite miners and alumina refiners by production volume, but sits outside the top-10 aluminum producers, a list dominated by Chinese companies. Profits are closely tied to prevailing commodity prices along the aluminum supply chain.Alcoa was the first mass producer of aluminum, launching the world-changing Hall-Heroult smelting process in the 1880s, making aluminum affordable. It listed as a public company in 1925. In 2016, Alcoa spun off its automotive and aerospace metal parts segment to focus on mining, smelting, and refining. It bought the 40% unowned balance of AWAC in mid-2024.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.